NEW YORK (GenomeWeb News) – Lumera’s life sciences subsidiary Plexera today said it has signed an option agreement for protein array technology from Harvard University spinout Auguron Biosciences.
 
The company said it will use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA), which was developed at the Harvard Institute of Proteomics, to generate functional proteins on high density microchips from surface printed DNA.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.